CFTR and cystic fibrosis: For CF patients with the most frequent mutation F508del, the best investigational drug is VX-809 (or lumacaftor, Vertex), reported to rescue ~ 25% CFTR activity in F508del/F508del primary human bronchial (HBE) cells (Van Goor et al., 2011).